Home / Central Data Catalog / AHRI.EVOLVE.HBV
central

EVOLVE-HBV (Evaluation of Vukuzazi LiVEr disease - Hepatitis B): A retrospective serosurvey of Hepatitis B Virus (HBV) infection, exposure, and vaccine-mediated immunity using archived samples from the Vukuzazi Study (2018-2020).

South Africa, 2018 - 2020
Get Microdata
Reference ID
AHRI.EVOLVE.HBV
Producer(s)
Siyabonga Nxumalo, Lusanda Mazibuko, Nompumelelo Mkwanazi, Prof Philippa C Matthews, Prof Collins Iwuji, Dr Motswedi Anderson, Kathy Baisley, Gregory Ording-Jespersen, Mark Siedner, Emily Wong, Willem Hanekom, Vukuzazi Field Team, Sample Processing Unit, Khanyi Msomi, Theresa Smit, Dickman Gareta,
Metadata
Documentation in PDF DDI/XML JSON
Created on
Jul 14, 2026
Last modified
Jul 14, 2026
Page views
639
Downloads
1
  • Identification
  • Version
  • Scope
  • Coverage
  • Producers and sponsors
  • Sampling
  • Data collection
  • Data processing
  • Data Access
  • Metadata production

    • Identification

    Survey ID number

    AHRI.EVOLVE.HBV
    Title

    EVOLVE-HBV (Evaluation of Vukuzazi LiVEr disease - Hepatitis B): A retrospective serosurvey of Hepatitis B Virus (HBV) infection, exposure, and vaccine-mediated immunity using archived samples from the Vukuzazi Study (2018-2020).
    Country
    Name Country code
    South Africa ZA
    Abstract

    The EVOLVE-HBV study was established in 2023 to provide evidence for resource allocation and intervention strategies that support progress toward hepatitis B (HBV) elimination targets. The serosurvey component of the programme aimed to:

    1. Quantify the prevalence of HBV infection, prior exposure, vaccine-mediated immunity and susceptibility;
    2. Describe the distribution of HBV serological markers according to demographic, clinical, HIV, non-communicable disease and spatial characteristics;
    3. Evaluate HBV viral load and alanine aminotransferase (ALT) levels among participants with evidence of HBV infection;
    4. Estimate the proportion of the population meeting critiera for HBV treatment eligibility under contemporary World Health Organization guidelines for HBV (2024).
    5. Describe the geographic distribution of HBV infection within the surveillance area.

    The study was nested within the Vukuzazi programme, conducted by the Africa Health Research Institute (AHRI) in the uMkhanyakude district of KwaZulu-Natal, South Africa. A stratified sample of 2,200 plasma specimens collected between 2018 and 2020 was retrospectively tested for HBV biomarkers and linked to sociodemographic, clinical, HIV, non-communicable disease and geospatial data.

    More information and study resources are available online here: https://doi.org/10.6084/m9.figshare.c.7678727
    Kind of Data

    Survey Data, clinical data, biomarker data, administrative records data, spatial data
    Unit of Analysis

    Individual-level cross-sectional data. Each record represents a single plasma sample collected during the Vukuzazi programme (2018-2020) from a participant aged 15 years or older. Samples were retrospectively tested for HBV biomarkers.

    Version

    Version Description

    V1.0.0

    Scope

    Topics
    Topic Vocabulary URI
    Hepatitis B virus; seroepidemiologic studies; coinfection; noncommunicable diseases; hepatitis, viral, human; HIV infections; public health surveillance; health status disparities; antiviral treatment; eligibility determination. Africa Health Research Institute www.ahri.org
    Keywords
    Hepatitis B; HBV; vaccine-mediated immunity; HIV co-infection; seroprevalence; rural health; KwaZulu-Natal; South Africa; population surveillance; archived plasma samples; liver disease; public health equity.

    Coverage

    Geographic Coverage

    Africa Health Research Institute (AHRI) demographic surveillance area in rural uMkhanyakude district, KwaZulu-Natal.
    Universe

    A subset of residents aged 15 years and older in the AHRI surveillance area who participated in the Vukuzazi health screening programme between May 2018 and March 2020.

    Producers and sponsors

    Primary investigators
    Name Affiliation
    Siyabonga Nxumalo AHRI
    Lusanda Mazibuko AHRI
    Nompumelelo Mkwanazi AHRI
    Prof Philippa C Matthews The Francis Crick Institute / University College London
    Prof Collins Iwuji AHRI
    Dr Motswedi Anderson AHRI
    Kathy Baisley AHRI / Harvard MGH
    Gregory Ording-Jespersen AHRI
    Mark Siedner AHRI / Harvard MGH
    Emily Wong AHRI / University of Alabama at Birmingham
    Willem Hanekom AHRI
    Vukuzazi Field Team AHRI
    Sample Processing Unit AHRI
    Khanyi Msomi National Health Laboratory Service
    Theresa Smit AHRI
    Dickman Gareta AHRI
    Luthando Zuma AHRI
    Producers
    Name
    Africa Health Research Institute
    Funding Agency/Sponsor
    Name Abbreviation Role
    The Francis Crick Institute (core funding to the Hepatitis B Elimination Lab, ref CC2223), drawing on funding from Wellcome, MRC and Cancer Research UK Crick Core Funding PI (Matthews)
    University College London Biomedical Research Centre (BRC NIHR BRC Contribution to salary funding (Matthews)
    AHRI Wellcome Strategic Core award Welcome Institutional core funding

    Sampling

    Sampling Procedure

    A stratified random sample of 2,200 plasma samples was selected from the Vukuzazi biobank. Stratification was done by age group, sex and HIV status, and samples were randomly selected within each stratum.

    Data collection

    Dates of Data Collection
    Start End
    2018-05-01 2020-03-31

    Data processing

    Data Editing

    All serological and molecular testing followed validated laboratory protocols. Data were cleaned, linked and de-identified prior to analysis. Spatial analysis used GIS shapefiles from AHRI's surveillance area.

    Data Access

    Access conditions

    Access to the data requires accurate completion of the online data access application form accessible on the AHRI Data repository(https://data.ahri.org/). Data users are required to abide by the data use conditions stipulated on the application for access to the data. Failure to do so may result in their data access privileges being revoked by the Data Custodian. In order to recognise the effort and intellectual contributions of AHRI investigators in producing and curating the data, users of AHRI data must acknowledge the source of the data and abide by the terms and conditions under which the data is accessed and must cite the dataset in publication using the citation provided as part of this documentation. All analytical datasets published on the AHRI Data Repository are assigned digital object identifier (DOIs) and the DOIs can be found on the Data Repository under Study Description tab - Access policy. AHRI data users are required to always cite the dataset using the relevant DOI.
    Citation requirements

    Nxumalo, S., Mazibuko, L., Mkwanazi, N., Matthews, P. C., Iwuji, C., Anderson, M., Baisley, K., Ording-Jespersen, G., Siedner, M., Wong, E., Hanekom, W., Africa Health Research Institute, Africa Health Research Institute, Msomi, K., Smit, T., Gareta, D., & Zuma, L. (2026). EVOLVE-HBV (Evaluation of Vukuzazi LiVEr disease - Hepatitis B): A retrospective serosurvey of Hepatitis B Virus (HBV) infection, exposure, and vaccine-mediated immunity using archived samples from the Vukuzazi Study (2018-2020) [Dataset]. Africa Health Research Institute.

    DOI: https://doi.org/10.23664/AHRI.EVOLVE.HBV

    Metadata production

    DDI Document ID

    AHRI.EVOLVE.HBV
    Producers
    Name Abbreviation
    Africa Health Research Institute AHRI
    Back to Catalog